Thyroid Autoimmunity in Girls with Turner Syndrome

Association of thyroid autoimmunity and the response to recombinant human growth hormone in Turner syndrome

10.1101/2020.09.13.20193573 ◽

2020 ◽

Author(s):

Yuyao Song ◽

Hongbo Yang ◽

Linjie Wang ◽

Fengying Gong ◽

Hui Pan ◽

...

Keyword(s):

Growth Hormone ◽

Turner Syndrome ◽

Human Growth Hormone ◽

Recombinant Human Growth Hormone ◽

Thyroid Autoimmunity ◽

Human Growth ◽

Height Velocity ◽

Thyroid Autoantibodies ◽

Thyroid Autoantibody ◽

Rhgh Treatment

Introduction: Short stature and thyroid autoimmunity are among the most common traits in Turner syndrome (TS). Recombinant human growth hormone (rhGH) treatment benefits height growth in Turner syndrome individuals when applicable. This study aims to investigate the association of thyroid autoimmunity and the response to rhGH treatment in Turner Syndrome patients. Methods: Medical records of 494 patients with TS were reviewed. Among 126 patients who regularly tested for thyroid autoantibodies, 108 patients had received rhGH treatment. Clinical characteristics, including karyotype and the presence of autoimmune thyroid diseases, as well as rhGH treatment records were analyzed. Height velocity (HV) of patients with or without thyroid autoimmunity was compared to assess the response to rhGH treatment. For patients who received rhGH treatment and positive for thyroid autoantibodies, height velocity before and after antibody presence was compared. Results: 45XO monosomy presented in 36% (176/496) of patients. 42.1% of patients (53/126) had elevated circulating anti-thyroid peroxidase antibody (TPOAb) and anti-thyroglobulin antibody (TgAb). In 108 patients who received rhGH treatment, a negative correlation was found between circulating TPOAb concentration and HV (n=53, r = -0.276, P<0.05). For patients who developed thyroid autoantibodies during rhGH treatment, HVs after thyroid autoantibody presence significantly decreased compared with HVs before thyroid autoantibody detection (n=44, p=0.0017). Conclusions: Our data suggested that in preadult TS patients who developed thyroid autoantibodies during rhGH treatment, the response to rhGH is negatively associated with the development of thyroid autoimmunity.

Download Full-text

Association of thyroid autoimmunity and the response to recombinant human growth hormone in Turner syndrome

Journal of Pediatric Endocrinology and Metabolism ◽

10.1515/jpem-2020-0610 ◽

2021 ◽

Vol 34 (4) ◽

pp. 465-471

Author(s):

Yuyao Song ◽

Hongbo Yang ◽

Linjie Wang ◽

Fengying Gong ◽

Hui Pan ◽

...

Keyword(s):

Growth Hormone ◽

Turner Syndrome ◽

Human Growth Hormone ◽

Recombinant Human Growth Hormone ◽

Thyroid Autoimmunity ◽

Human Growth ◽

Height Velocity ◽

Thyroid Autoantibodies ◽

Thyroid Autoantibody ◽

Rhgh Treatment

Abstract Objectives Short stature and thyroid autoimmunity are common comorbidities in Turner syndrome (TS). Recombinant human growth hormone (rhGH) significantly improves height growth in TS individuals. This study aims to investigate the association of thyroid autoimmunity and the response to rhGH treatment in TS patients. Methods Medical records of 494 patients with TS were reviewed. Among 126 patients who regularly tested for thyroid autoantibodies, 108 patients had received rhGH treatment. Clinical characteristics, including karyotype and the presence of autoimmune thyroid diseases, as well as rhGH treatment records were analyzed. Height velocity (HV) of patients with or without thyroid autoimmunity was compared to assess the response to rhGH treatment. For patients who developed thyroid autoantibodies during rhGH treatment, HV before and after antibody presence were compared. Results 45XO monosomy presented in 36% (176/496) of patients. 42.1% of patients (53/126) had elevated circulating anti-thyroid peroxidase antibody and anti-thyroglobulin antibody. In 108 patients who received rhGH treatment, HVs were significantly correlated to age, height, weight and BMI at the initiation of treatment. For patients who developed thyroid autoantibodies during rhGH treatment, HVs after thyroid autoantibody presence significantly decreased compared with HVs before thyroid autoantibody detection (n=44, p=0.0017). Conclusions Our data suggested that in TS patients who developed thyroid autoantibodies during rhGH treatment, the response to rhGH is negatively associated with the development of thyroid autoimmunity.

Download Full-text